AR040476A1 - N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) - Google Patents

N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)

Info

Publication number
AR040476A1
AR040476A1 AR20030102464A ARP030102464A AR040476A1 AR 040476 A1 AR040476 A1 AR 040476A1 AR 20030102464 A AR20030102464 A AR 20030102464A AR P030102464 A ARP030102464 A AR P030102464A AR 040476 A1 AR040476 A1 AR 040476A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkyl group
alkyl
fluoro
Prior art date
Application number
AR20030102464A
Other languages
English (en)
Inventor
Emma Margareta Sigfridsson
Anna Stina Maria Linusson
Pernilla Marie Sandberg
Anette Marie Svensson
Tord Inghardt
Kay Brickmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR040476A1 publication Critical patent/AR040476A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Procesos para preparar dichos compuestos, su uso en el tratamiento de obesidad, trastornos psiquiátricos, trastornos cognitivos, trastornos de la memoria, esquizofrenia, epilepsia y estados relacionados, y trastornos neurológicos tales como demencia, esclerosis múltiple, enfermedad de Parkinson, corea de Huntington y enfermedad de Alzheimer, así como trastornos relacionados con el dolor y composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: R1 representa un grupo alcoxi C1-4 optativamente sustituido por uno o más fluoro o un grupo alquilo C1-4 optativamente sustituido por uno o más fluoro; n representa 0 ó 1; R2 representa un grupo alquilo C1-4 optativamente sustituido por uno o más fluoro o un grupo alcoxi C1-4 optativamente sustituido por uno o más fluoro; m representa 0 ó 1; R3 representa H o un grupo alquilo C1-4; L1 representa una cadena alquileno (CH2)r en la cual representa 2 ó 3 ó L1 representa un grupo ciclohexilo donde los dos nitrógenos que llevan R3 y R4, respectivamente, están unidos al grupo ciclohexilo ya sea a través de las posiciones 1,3 ó 1,4 del grupo ciclohexilo o L1 representa un grupo ciclopentilo donde los dos nitrógenos que llevan R3 y R4, respectivamente, están unidos al grupo ciclopentilo a través de la posición 1,3 del grupo ciclopentilo y además cuando R5 representa 9,10-metanoantracen-9(10H)-ilo el grupo -L1-N(R4)- junto representa un anillo piperidilo que está unido a 12 a través del nitrógeno del piperidinilo y a N-R3 a través de la posición 4 del anillo piperidilo con la condición de que, cuando R5 representa 9,10-metanoantracen-9(10H)-ilo entonces r es solamente 2; R4 representa H o un grupo alquilo C1-4 optativamente sustituido por uno o más de los siguientes: un grupo arilo o un grupo heteroarilo; L2 representa un enlace o una cadena alquileno (CH2)2 en la cual s representa 1, 2, ó 3 donde la cadena alquileno se sustituye optativamente por uno o más de los siguientes: un grupo alquilo C1-4, fenilo o heteroarilo; R5 representa arilo, un grupo heterocíclico o un grupo cicloalquilo C3-8 que está optativamente fusionado a un grupo fenilo o a heteroarilo; así como los isómeros ópticos y racematos de los mismos y las sales aceptables para uso farmacéutico de los mismos; con la primera condición de que cuando n es 0, y m es 1 y R2 es metilo ubicado en la posición 4 del anillo quinolina, y R3 es H y R4 es H y L1 es (CH2)2 o (CH2)3 o 1,4-ciclohexilo; y L2 es un enlace, entonces R5 no es 4-metilquinolin-2-ilo; y con una segunda condición de que cuando n es 0, y m es 0 ó 1 y R2 es un grupo alcoxi C1-3 ubicado en la posición 4 del anillo quinolina, y R3 es H o un grupo alquilo C1-3 y R4 es H o un grupo alquilo C1-3 y L1 es (CH2)3 y L2 es metileno optativamente sustituido por uno o más grupos alquilo C1-3 o fenilo, entonces R5 no es fenilo, tienilo o indolilo optativamente sustituido por uno, dos o tres grupos alquilo C1-4 o halo.
AR20030102464A 2002-07-08 2003-07-08 N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) AR040476A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR040476A1 true AR040476A1 (es) 2005-04-06

Family

ID=20288471

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102464A AR040476A1 (es) 2002-07-08 2003-07-08 N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)

Country Status (19)

Country Link
US (1) US20060247439A1 (es)
EP (1) EP1528924A1 (es)
JP (1) JP2006501186A (es)
CN (1) CN1665502A (es)
AR (1) AR040476A1 (es)
AU (1) AU2003281194A1 (es)
BR (1) BR0312312A (es)
CA (1) CA2491835A1 (es)
CO (1) CO5680403A2 (es)
IL (1) IL165841A0 (es)
IS (1) IS7653A (es)
MX (1) MXPA05000336A (es)
NO (1) NO20045528L (es)
PL (1) PL374674A1 (es)
RU (1) RU2004138079A (es)
SE (1) SE0202134D0 (es)
TW (1) TW200412957A (es)
WO (1) WO2004004726A1 (es)
ZA (1) ZA200500030B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
ZA200507112B (en) * 2003-03-31 2007-03-28 Taisho Pharmaceutical Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1706384A1 (en) * 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006035967A1 (en) * 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
ATE446962T1 (de) * 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
US7750034B2 (en) 2006-01-25 2010-07-06 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
BRPI0717140A2 (pt) * 2006-09-28 2013-10-22 Hoffmann La Roche Derivados de quinolina com propriedades de ligação de 5-ht
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
BR112012013431B1 (pt) 2009-12-04 2022-04-12 Sunovion Pharmaceuticals, Inc. Composto e seu uso, composição farmacêutica
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2017301769B2 (en) 2016-07-29 2022-07-28 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CA3047404A1 (en) * 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
IL303177A (en) 2017-02-16 2023-07-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
JP7453148B2 (ja) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク 塩、結晶形態、およびその製造方法
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020283A (en) * 1958-10-20 1962-02-06 Abbott Lab Bis-lepidines
AU7997091A (en) * 1990-05-30 1991-12-31 American Home Products Corporation Substituted arylsulfonamides and benzamides
JP2001525793A (ja) * 1996-05-14 2001-12-11 ノボ ノルディスク アクティーゼルスカブ ソマトスタチンの作動因子及び拮抗因子
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
KR20010043131A (ko) * 1998-04-29 2001-05-25 피터 기딩스 Ｍｒｓ 억제제 및 살균제로서 사용되는 퀴놀론
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
JPWO2002051836A1 (ja) * 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
EP1359915A4 (en) * 2001-01-26 2004-07-21 Smithkline Beecham UROTENSIN-II RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
US20060247439A1 (en) 2006-11-02
IS7653A (is) 2005-01-19
CO5680403A2 (es) 2006-09-29
SE0202134D0 (sv) 2002-07-08
PL374674A1 (en) 2005-10-31
IL165841A0 (en) 2006-01-15
TW200412957A (en) 2004-08-01
JP2006501186A (ja) 2006-01-12
CN1665502A (zh) 2005-09-07
NO20045528L (no) 2005-04-04
WO2004004726A1 (en) 2004-01-15
AU2003281194A1 (en) 2004-01-23
MXPA05000336A (es) 2005-03-31
EP1528924A1 (en) 2005-05-11
CA2491835A1 (en) 2004-01-15
BR0312312A (pt) 2005-04-12
ZA200500030B (en) 2005-11-11
RU2004138079A (ru) 2005-08-10

Similar Documents

Publication Publication Date Title
AR040476A1 (es) N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
AR051290A1 (es) Derivados de hidantoina sustituidas
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR050435A1 (es) DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
AR051802A1 (es) Heterociclos antagonistas de mchr1
AR038183A1 (es) Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
KR927003052A (ko) 2-아릴티아졸 유도체 및 그의 약제학적 조성물
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
ECSP088431A (es) Derivados de pirazolo
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
AR043046A1 (es) Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparacion
AR047901A1 (es) Inhibidores de proteasa ns3 del virus de la hepatitis c
AR055959A1 (es) Derivados espiro para la modulacion de actividad de crth2
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
AR047369A1 (es) N-cicloalquil, aril o heteroaril-n??-quinolin-2-ilcicloalquildiaminas, procesos para preparar tales compuestos y composiciones farmaceuticas que las contienen
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR060268A1 (es) Tiazolil - dihidro - indazoles
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
SE0101579D0 (sv) New compounds
DK1717229T3 (da) Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino

Legal Events

Date Code Title Description
FB Suspension of granting procedure